ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings
17 oct. 2022 08h30 HE
|
ChemoCentryx, Inc.
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS® (avacopan) for patients with ANCA-associated vasculitis; additional poster will...
ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
05 oct. 2022 08h30 HE
|
ChemoCentryx, Inc.
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS,...
ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences
24 août 2022 08h30 HE
|
ChemoCentryx, Inc.
SAN CARLOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned poster presentations at three upcoming medical conferences taking place in August...
ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call
09 août 2022 08h30 HE
|
ChemoCentryx, Inc.
SAN CARLOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for...
ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022
02 août 2022 16h05 HE
|
ChemoCentryx, Inc.
SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2022 financial results will be released after market close...
ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director
05 juil. 2022 08h30 HE
|
ChemoCentryx, Inc.
SAN CARLOS, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Jennifer L. Herron has been appointed to the Board as an independent director,...
ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
06 juin 2022 08h30 HE
|
ChemoCentryx, Inc.
-- Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in first cycle of treatment -- -- Safety and tolerability allow for continued dose escalation...
ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferences
31 mai 2022 16h05 HE
|
ChemoCentryx, Inc.
SAN CARLOS, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming abstract presentations at three key medical conferences taking place in June, which...
ChemoCentryx Announces Changes to its Board of Directors
31 mai 2022 08h30 HE
|
ChemoCentryx, Inc.
-- David E. Wheadon, M.D., Elected to the Board as an Independent Director -- -- Henry A. McKinnell, Jr., to Retire from Board -- SAN CARLOS, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx,...
ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis Suppurativa
18 mai 2022 08h30 HE
|
ChemoCentryx, Inc.
-- Supports plans to advance TAVNEOS®(avacopan) into Phase III development for the treatment of patients with most severe form of hidradenitis suppurativa, Hurley Stage III -- SAN CARLOS, Calif., May...